Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy with or without maximal tumor debulking for multi-organ metastatic colorectal cancer
2011-005003-32Phase 3Active
- Sponsor
- VU University Medical Center, Department of Medical Oncology
- Start
- Mar 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, bevacizumab, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by VU University Medical Center, Department of Medical Oncology. Primary endpoint: Overall survival. Started Mar 2012; status: active.
02
Drugs
capecitabineoxaliplatinbevacizumabfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2011-005003-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005003-32.